An algorithm for guiding clinical judgments about the futility of anti-VEGF treatment of neovascular age-related macular degeneration (nvAMD) has importance from clinical, ethical, and legal perspectives and would be a valuable decision-making tool for retina specialists and payors, according to David T. Wong, MD.
There are a number of ongoing clinical trials investigating treatments for dry age-related macular degeneration (AMD). These modalities include medications that are already in use for other indications and investigational agents representing various novel mechanisms of action.
New technology has been paired with the time-tested technique of direct ophthalmoscopy to create a portable, retinal imaging system (D-Eye, D-Eye S.r.l.) that utilizes a small optical device magnetically attached to a smartphone.
The scientific community knows that vascular endothelial growth factor (VEGF) causes increased, vascular permeability, resulting in diabetic macular edema (DME) in the ischemic retina, but how to stop the VEGF drive remains the challenge.
The Diabetic Retinopathy Clinical Research Network’s (DRCR.net) Protocol T—the first head-to-head-to-head comparison among aflibercept (Eylea, Renegeron Pharmaceuticals), ranibizumab (Lucentis, Genentech), and bevacizumab (Avastin, Genentech)—found in its first-year results that all three agents improved vision and reduced edema effectively.
New imaging technologies, such as ultra-wide-field fluorescein angiography and optical coherence tomography angiography, are providing more details about retinal diseases than previous imaging technologies, leading to better understanding of disease processes.